Choice Equity Broking, too, expects muted growth for the drugmaker because of a decline in margins due to a change in product mix and operating de-leverage
Choice Equity Broking, too, expects muted growth for the drugmaker because of a decline in margins due to a change in product mix and operating de-leverage Choice Equity Broking, too, expects muted growth for the drugmaker because of a decline in margins due to a change in product mix and operating de-leverage Moneycontrol Latest News Read More
English 
हिन्दी